New meta-analysis further supports low re-excisions and high placement accuracy with the Magseed marker

An independent meta-analysis from January 2026, pooling 2,117 patients and 2,176 Magseed marker placements, has reported low re-excision rates (8.2%) and low positive margins (7.6%) when the marker is used to localise non-palpable breast lesions prior to breast‑conserving surgery (BCS).
Al Darwashi et al. (2026) pooled 16 studies to evaluate safety and efficacy outcomes when the Magseed marker was used for preoperative localisation of non-palpable lesions prior to BCS.
The authors reported high placement accuracy, reliable intraoperative retrieval and low rates of positive margins, re-excisions and complications.
In a cohort cited by the review, Moreno‑Palacios et al. (2024) also observed that Magseed marker facilitates less extensive resections compared to guidewires, promising improved cosmetic outcomes while maintaining oncological efficacy.
The key findings
Low re-operation burden: Positive margins occurred in just 7.6% of cases, and only 8.2% required re-excision across the included series.
High placement accuracy: The success rate for Magseed marker placement showed 99.3% positioned within 10 mm of the lesion.
Of note, 96.6% of Magseed markers were placed within an even stricter 5 mm radius.
Reliable retrieval: The pooled intraoperative retrieval success was 99.6% for the Magseed® marker.
“This meta-analysis demonstrated Magseed as a safe and effective preoperative localisation technique for BCS in the management of selected non-palpable breast lesions.” Al Darwashi et al. (2026)
Ready to find out more about the Magseed marker and the Sentimag system?
→ Speak to a Magseed marker expert
Magseed® is a trademark of Hologic, Inc. or its subsidiaries in the United States or other countries. Intended for medical professionals and use in the U.S., UK and the EU only.
Newsletter
Sign up for free weekly updates
The latest femtech news, research and investment, straight to your inbox.










